BACKGROUND: The World Health Organization advocates 2-3 doses of sulfadoxine-pyrimethamine (SP) for intermittent preventive treatment of malaria (SP IPTp). The optimal number of doses and the consequences of single-dose therapy remain unclear. METHODS: Data were from a randomized, controlled study of human immunodeficiency virus-positive Zambian women comparing monthly versus 2-dose SP IPTp. We compared maternal and neonatal birth outcomes as a function of how many doses the mothers received (1 to > or =4 doses). RESULTS: Of 387 deliveries, 34 received 1 dose of SP. Single-dose SP was significantly associated with higher proportions of maternal anemia, peripheral and cord blood parasitemia, infant prematurity, and low birth weight. SP conferred dose-dependent benefits, particularly in the transition from 1 to 2 doses of SP. Women randomized to the standard 2-dose regimen were much more likely to receive only 1 dose than were women randomized to monthly IPT (relative risk, 16.4 [95% confidence interval, 4.0-68.3]). CONCLUSIONS: Single-dose SP was a common result of trying to implement the standard 2-dose regimen and was inferior to all other dosing regimens. At a programmatic level, this implies that monthly SP IPTp may ultimately be more effective than the standard regimen by reducing the risk of inadvertently underdosing mothers.
RCT Entities:
BACKGROUND: The World Health Organization advocates 2-3 doses of sulfadoxine-pyrimethamine (SP) for intermittent preventive treatment of malaria (SP IPTp). The optimal number of doses and the consequences of single-dose therapy remain unclear. METHODS: Data were from a randomized, controlled study of human immunodeficiency virus-positive Zambian women comparing monthly versus 2-dose SP IPTp. We compared maternal and neonatal birth outcomes as a function of how many doses the mothers received (1 to > or =4 doses). RESULTS: Of 387 deliveries, 34 received 1 dose of SP. Single-dose SP was significantly associated with higher proportions of maternal anemia, peripheral and cord blood parasitemia, infant prematurity, and low birth weight. SP conferred dose-dependent benefits, particularly in the transition from 1 to 2 doses of SP. Women randomized to the standard 2-dose regimen were much more likely to receive only 1 dose than were women randomized to monthly IPT (relative risk, 16.4 [95% confidence interval, 4.0-68.3]). CONCLUSIONS: Single-dose SP was a common result of trying to implement the standard 2-dose regimen and was inferior to all other dosing regimens. At a programmatic level, this implies that monthly SP IPTp may ultimately be more effective than the standard regimen by reducing the risk of inadvertently underdosing mothers.
Authors: Steve M Taylor; Alejandro L Antonia; Ebbie Chaluluka; Victor Mwapasa; Gaoqian Feng; Malcolm E Molyneux; Feiko O ter Kuile; Steven R Meshnick; Stephen J Rogerson Journal: Clin Infect Dis Date: 2012-03-22 Impact factor: 9.079
Authors: Abraham R Oduro; David J Fryauff; Kwadwo A Koram; William O Rogers; Francis Anto; Frank Atuguba; Thomas Anyorigiya; Martin Adjuik; Patrick Ansah; Abraham Hodgson; Francis Nkrumah Journal: Am J Trop Med Hyg Date: 2010-07 Impact factor: 2.345
Authors: Verner N Orish; Onyekachi S Onyeabor; Johnson N Boampong; Richmond Afoakwah; Ekene Nwaefuna; Samuel Acquah; Adekunle O Sanyaolu; Nnaemeka C Iriemenam Journal: Afr Health Sci Date: 2015-12 Impact factor: 0.927
Authors: Kassoum Kayentao; Paul Garner; Anne Maria van Eijk; Inbarani Naidoo; Cally Roper; Abdunoor Mulokozi; John R MacArthur; Mari Luntamo; Per Ashorn; Ogobara K Doumbo; Feiko O ter Kuile Journal: JAMA Date: 2013-02-13 Impact factor: 56.272
Authors: Mari Luntamo; Anne-Maria Rantala; Steven R Meshnick; Yin Bun Cheung; Teija Kulmala; Kenneth Maleta; Per Ashorn Journal: PLoS One Date: 2012-07-19 Impact factor: 3.240
Authors: Atupele Kapito-Tembo; Steven R Meshnick; Michaël Boele van Hensbroek; Kamija Phiri; Margaret Fitzgerald; Victor Mwapasa Journal: J Infect Dis Date: 2011-01-07 Impact factor: 5.226